Bristol Myers Squibb's Opdivo Plus Yervoy Combo Shows Durable, Long-Term Survival In Lung Cancer Patients
Portfolio Pulse from Vandana Singh
Bristol Myers Squibb & Co (BMY) announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, demonstrating long-term survival benefits of Opdivo plus Yervoy in the treatment of metastatic non-small cell lung cancer. The company also shared results from a Phase 2 study evaluating BMS-986278 in patients with progressive pulmonary fibrosis, showing a reduction in the rate of decline in percent predicted forced vital capacity. BMY shares are up 0.41% at $61.07.
September 11, 2023 | 6:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb announced positive results from trials of Opdivo plus Yervoy and BMS-986278, which could potentially boost its stock.
The announcement of positive results from the trials of Opdivo plus Yervoy and BMS-986278 is a significant development for Bristol Myers Squibb. This could potentially lead to increased sales and revenue for the company, which would likely have a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100